An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease.
Saved in:
| Title: | An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease. |
|---|---|
| Authors: | Kumar, Rajeev1 (AUTHOR) rajeev_kumar@msn.com, Agarwal, Pinky2 (AUTHOR), Anderson, Karen3 (AUTHOR), Claassen, Daniel4 (AUTHOR), Dean, Marissa5 (AUTHOR), Duker, Andrew6 (AUTHOR), Scott, Burton7 (AUTHOR), Hoehn, Benjamin8 (AUTHOR), Mongan, Ann8 (AUTHOR), Lin, Ping8 (AUTHOR), Cahir‐McFarland, Ellen8 (AUTHOR), Taylor, Lori8 (AUTHOR), Morrison, Glenn8 (AUTHOR), Yednock, Ted8 (AUTHOR), Keswani, Sanjay8 (AUTHOR), Kroon, Henk‐Andre8 (AUTHOR) |
| Source: | Movement Disorders. Jun2026, Vol. 41 Issue 6, p1492-1501. 10p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
